Oncosec Medical (NASDAQ: ONCS) is a biotechnology company that designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. For more information, visit the company’s website at www.oncosec.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
